Small molecule allosteric inhibitor BTYNB (IC50 = 2.3 μM in ES-2, = 3.6 μM in IGROV-1, = 4.5 μM in SK-MEL2) has been identified to hinder the proliferation of IGF2BP1-overexpressing ovarian cancer and melanoma cells by altering the functional site of IGF2BP1 and decreasing the expression of downstream oncogenes, including MYC, BTRC, and eEF2 [116]. This evidence concerns the gene IGF2BP1 and ovarian cancer.